Kenneth E. Palmer

5.0k total citations
84 papers, 3.3k citations indexed

About

Kenneth E. Palmer is a scholar working on Molecular Biology, Infectious Diseases and Biotechnology. According to data from OpenAlex, Kenneth E. Palmer has authored 84 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 23 papers in Infectious Diseases and 23 papers in Biotechnology. Recurrent topics in Kenneth E. Palmer's work include Transgenic Plants and Applications (23 papers), Plant Virus Research Studies (21 papers) and HIV Research and Treatment (16 papers). Kenneth E. Palmer is often cited by papers focused on Transgenic Plants and Applications (23 papers), Plant Virus Research Studies (21 papers) and HIV Research and Treatment (16 papers). Kenneth E. Palmer collaborates with scholars based in United States, South Africa and Belgium. Kenneth E. Palmer's co-authors include Edward P. Rybicki, Alison A. McCormick, Barry R. O’Keefe, James B. McMahon, Gregory P. Pogue, Amanda B. Lasnik, Fakhrieh Vojdani, J. Calvin Kouokam, Mark L. Smith and Nobuyuki Matoba and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kenneth E. Palmer

83 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth E. Palmer United States	33	1.5k	969	787	693	480	84	3.3k
Larry Zeitlin United States	32	1.1k 0.8×	1.1k 1.2×	1.5k 1.9×	252 0.4×	840 1.8×	90	3.5k
Susan L. Welkos United States	46	4.0k 2.6×	650 0.7×	1.1k 1.4×	400 0.6×	509 1.1×	111	5.7k
Vidadi Yusibov United States	41	3.0k 2.0×	3.0k 3.1×	983 1.2×	1.5k 2.1×	639 1.3×	108	5.1k
Conrad P. Quinn United States	38	2.5k 1.6×	448 0.5×	750 1.0×	113 0.2×	320 0.7×	92	3.2k
Kees Leenhouts Netherlands	38	2.4k 1.6×	683 0.7×	696 0.9×	318 0.5×	536 1.1×	70	4.5k
Les Baillie United Kingdom	33	2.2k 1.4×	462 0.5×	681 0.9×	149 0.2×	200 0.4×	100	2.9k
Stephen J. Streatfield United States	31	2.9k 1.9×	2.8k 2.9×	770 1.0×	1.1k 1.5×	291 0.6×	67	4.3k
Stefania Conti Italy	31	1.4k 0.9×	397 0.4×	1.0k 1.3×	614 0.9×	1.0k 2.1×	181	4.0k
Bruce E. Ivins United States	33	3.5k 2.3×	664 0.7×	1.3k 1.7×	101 0.1×	432 0.9×	55	4.1k
Laurence A. Mulard France	27	1.2k 0.8×	244 0.3×	582 0.7×	135 0.2×	200 0.4×	93	2.2k

Countries citing papers authored by Kenneth E. Palmer

Since Specialization

Citations

This map shows the geographic impact of Kenneth E. Palmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth E. Palmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth E. Palmer more than expected).

Fields of papers citing papers by Kenneth E. Palmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth E. Palmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth E. Palmer. The network helps show where Kenneth E. Palmer may publish in the future.

Co-authorship network of co-authors of Kenneth E. Palmer

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth E. Palmer. A scholar is included among the top collaborators of Kenneth E. Palmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth E. Palmer. Kenneth E. Palmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brand, Rhonda M., Lisa C. Rohan, Lin Wang, et al.. (2023). A topical rectal douche product containing Q-Griffithsin does not disrupt the epithelial border or alter CD4+ cell distribution in the human rectal mucosa. Scientific Reports. 13(1). 7547–7547. 3 indexed citations

Keith, Rachel J., Krystal T. Hamorsky, Kenneth E. Palmer, et al.. (2022). Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination. Vaccines. 10(8). 1363–1363. 6 indexed citations

Nabeta, Henry W., Maryam Zahin, Joshua L. Fuqua, et al.. (2022). A Phase 1a/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis. ThinkIR: The University of Louisville's Institutional Repository (University of Louisville). 6(1). 6 indexed citations

Rouchka, Eric C., Julia H. Chariker, Robert S. Adcock, et al.. (2021). Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Scientific Reports. 11(1). 15715–15715. 13 indexed citations

Nabeta, Henry W., J. Calvin Kouokam, Amanda B. Lasnik, Joshua L. Fuqua, & Kenneth E. Palmer. (2021). Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin. Microbiology Spectrum. 9(2). e0095721–e0095721. 13 indexed citations

Lo, Michael K., Jessica R. Spengler, Lauren R. H. Krumpe, et al.. (2020). Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge. The Journal of Infectious Diseases. 221(Supplement_4). S480–S492. 44 indexed citations

Ramírez, Julio A., et al.. (2020). Louisville Coronavirus Surveillance Program. 4(1). 3. 1 indexed citations

Hamorsky, Krystal T., et al.. (2020). Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector. Journal of Biotechnology. 320. 74–76. 4 indexed citations

Arnold, Forest W., Kamran Mahmood, Anupama Raghuram, et al.. (2020). COPD exacerbation caused by SARS-CoV-2: A Case Report from the Louisville COVID-19 Surveillance Program. ThinkIR: The University of Louisville's Institutional Repository (University of Louisville). 4(1). 1 indexed citations

10.

Lasnik, Amanda B., Longyun Zhang, Mohamed Y. Mahmoud, et al.. (2020). Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections. Journal of Controlled Release. 321. 84–99. 34 indexed citations

11.

Günaydın, Gökçe, Gabriella Edfeldt, David A. Garber, et al.. (2019). Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa. Scientific Reports. 9(1). 18120–18120. 19 indexed citations

12.

Birse, Kenzie, Johanna B. Holm, Pawel Gajer, et al.. (2018). Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates. Scientific Reports. 8(1). 8059–8059. 29 indexed citations

13.

Fuqua, Joshua L., Valentine Wanga, & Kenneth E. Palmer. (2015). Improving the large scale purification of the HIV microbicide, griffithsin. BMC Biotechnology. 15(1). 12–12. 33 indexed citations

14.

Férir, Geoffrey, Dana Huskens, Kenneth E. Palmer, et al.. (2012). Combinations of Griffithsin with Other Carbohydrate-Binding Agents Demonstrate Superior Activity Against HIV Type 1, HIV Type 2, and Selected Carbohydrate-Binding Agent-Resistant HIV Type 1 Strains. AIDS Research and Human Retroviruses. 28(11). 1513–1523. 37 indexed citations

15.

Banerjee, Kaustuv, Elizabeth Michael, Dirk Eggink, et al.. (2011). Occluding the Mannose Moieties on Human Immunodeficiency Virus Type 1 gp120 with Griffithsin Improves the Antibody Responses to Both Proteins in Mice. AIDS Research and Human Retroviruses. 28(2). 206–214. 28 indexed citations

16.

Shephard, Enid, et al.. (2011). The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine. Virology Journal. 8(1). 51–51. 19 indexed citations

17.

O’Keefe, Barry R., Fakhrieh Vojdani, Viviana Buffa, et al.. (2009). Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proceedings of the National Academy of Sciences. 106(15). 6099–6104. 208 indexed citations

18.

Smith, Mark L., John A. Lindbo, Paul Brosio, et al.. (2006). Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology. 348(2). 475–488. 139 indexed citations

19.

McCormick, Alison A., et al.. (2004). Using tobacco mosaic virus epitope display to enhance papillomavirus L2 antigen presentation. Cancer Research. 64. 290–290. 1 indexed citations

20.

Gates, D. J., John Rickard, Kenneth E. Palmer, et al.. (1977). BAZ volume 17 issue 3 Cover and Front matter. Bulletin of the Australian Mathematical Society. 17(3). f1–f4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact